Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJRW | ISIN: SE0015244520 | Ticker-Symbol: BIX0
München
08.11.24
08:05 Uhr
3,910 Euro
+0,065
+1,69 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOINVENT INTERNATIONAL AB Chart 1 Jahr
5-Tage-Chart
BIOINVENT INTERNATIONAL AB 5-Tage-Chart

Aktuelle News zur BIOINVENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
31.10.BIOINVENT INTERNATIONAL AB: BioInvent anticipates strong influx of clinical data1
31.10.BioInvent International AB: Interim Report January-September 2024152LUND, SWEDEN / ACCESSWIRE / October 31, 2024 / BioInvent International (STO:BINV) "Progress to date brings the company one step closer to addressing the needs for new treatment solutions for patients....
► Artikel lesen
29.10.BioInvent International: Invitation to Presentation of BioInvent's Interim Report January - September 2024149LUND, SE / ACCESSWIRE / October 29, 2024 / BioInvent International (STO:BINV)BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) invites investors, analysts and the press to a presentation...
► Artikel lesen
16.09.BIOINVENT INTERNATIONAL AB: BioInvent's CMO comments on the ESMO presentation7
14.09.BioInvent International: BioInvent and Transgene's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments461LUND, SWEDEN / ACCESSWIRE / September 14, 2024 / BioInvent International (STO:BINV)Preliminary data presented at ESMO 2024 demonstrate BT-001 induces tumor regression in patients who failed previous...
► Artikel lesen
14.09.Transgene S.A.: Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments454Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma...
► Artikel lesen
13.09.BIOINVENT INTERNATIONAL AB: BioInvent makes a strong entrance at ESMO in Barcelona1
12.09.BioInvent International: BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma178First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024Clinical supply agreement for acalabrutinib with AstraZeneca in placeLUND...
► Artikel lesen
09.09.BioInvent International: BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program593LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV)Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma...
► Artikel lesen
09.09.BioInvent International: BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024612LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV)BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients.Promising efficacy...
► Artikel lesen
09.09.Transgene S.A.: Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 20243
02.09.BIOINVENT INTERNATIONAL AB: BioInvent anticipates a continued data-rich 20241
29.08.BioInvent International reports Q2 results1
29.08.BioInvent International AB: Interim Report January-June 2024266LUND, SWEDEN / ACCESSWIRE / August 29, 2024 / BioInvent International (STO:BINV)"The presentation of promising results from our two lead drug candidates at the ASCO Annual Meeting showcased their potential...
► Artikel lesen
30.07.BioInvent International: BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application324Allowed US patent application for anti-TNFR2 antibody BI-1910 covers composition-of-matter protection and the use of antibody to treat cancerPatent will further strengthen IP protection of BioInvent's...
► Artikel lesen
22.07.BioInvent International: BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO1.204LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV)Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs:Progress...
► Artikel lesen
22.07.Transgene S.A.: Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 20244
19.07.BIOINVENT INTERNATIONAL AB: BioInvent and MSD to evaluate new metastatic melanoma treatment3
17.07.BioInvent International: BioInvent Announces New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1607 in Combination with KEYTRUDA and Ipilimumab523LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV)Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanomaThe study...
► Artikel lesen
26.06.BioInvent International: BioInvent Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 at PAGE 2024250Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown...
► Artikel lesen
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1